Last updated: April 25, 2026
Which suppliers make or source naltrexone hydrochloride API?
Naltrexone hydrochloride is typically supplied either as (1) active pharmaceutical ingredient (API) or (2) finished tablets for commercialization. For R&D and formulation work, the API supply chain is usually built through API manufacturers that also sell drug substance to branded generics and contract manufacturers.
Common supplier/manufacturer pathways used in the naltrexone hydrochloride value chain:
- API manufacturers and licensed exporters that produce naltrexone HCl API (or produce under contract for brand and generic developers).
- Finished-dose manufacturers that produce naltrexone hydrochloride tablets under commercial supply agreements (often supplying directly for clinical and commercial markets when drug substance sourcing is bundled).
Which finished-dose manufacturers supply naltrexone hydrochloride tablets?
Naltrexone hydrochloride tablets are widely commercialized as generic and branded products. Finished-dose supply is handled by many generic manufacturers and by label holders for brand markets, with product availability varying by country, dosage strength, and regulatory pathway.
A practical way to identify concrete, transaction-relevant suppliers is to map by:
- Product strength (commonly 50 mg tablets in many markets)
- Regulatory filings (where available) tied to label and manufacturing site
- Market authorization holder and manufacturer of record listed for each product
What specification and form standards typically apply to naltrexone hydrochloride?
Suppliers generally offer naltrexone hydrochloride in API form as a salt (hydrochloride). For CMC-facing procurement, buyers typically qualify based on:
- Salt form: naltrexone hydrochloride
- Solid-state form/grade controls per supplier COA
- Impurity profile and regulatory compliance (market-specific)
- Packaging: bulk drums, cartons, and tamper-evident containers depending on supplier and customer requirements
Supplier landscape: how the market is usually structured
Because naltrexone HCl is a mature molecule, sourcing usually concentrates in:
- Well-established API suppliers (repeat customers across multiple generics)
- Regional finished-dose manufacturers (especially for markets that require local packaging and release)
In practice, buyers should treat “naltrexone hydrochloride supplier” as two different procurement categories:
- API supplier (drug substance)
- Finished-dose supplier (drug product)
Key due-diligence checks procurement teams use for naltrexone hydrochloride
Before qualifying any supplier, teams typically verify:
- GMP status for drug substance manufacturing and testing
- CoA-based confirmation of key parameters (identity, assay, water content/LODs, related substances)
- Stability data and storage conditions
- Supply continuity and lot release controls
Key Takeaways
- Naltrexone hydrochloride supply is commonly split between API manufacturers (drug substance) and finished-dose manufacturers (tablets).
- For actionable supplier selection, procurement teams match suppliers to API vs finished-dose needs, then qualify by GMP, COA specs, impurity profile, and stability.
- Because naltrexone hydrochloride is mature and widely genericized, the fastest path to concrete vendor identification is mapping market authorization holders and manufacturing sites for the relevant dosage form in the target geography.
FAQs
-
Is naltrexone hydrochloride typically purchased as API or tablets?
Buyers usually choose API for direct formulation work and tablets when sourcing for clinical use without in-house formulation.
-
What dosage strength is most commonly sold for naltrexone hydrochloride tablets?
Many markets widely commercialize 50 mg naltrexone hydrochloride tablets, though local offerings vary.
-
Do suppliers offer naltrexone hydrochloride in different salt forms?
Procurement focuses on naltrexone hydrochloride specifically because the salt form affects specification and handling.
-
What is the most critical qualification document for supplier onboarding?
Supplier COAs combined with evidence of GMP compliance and controlled impurity specifications.
-
How do procurement teams identify qualified suppliers faster?
By cross-referencing finished-dose product manufacturers and sites in the target market and then tracing back to upstream drug substance sourcing paths.
Sources (APA)
[1] U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA Approved Drug Products. https://www.accessdata.fda.gov/scripts/cder/daf/
[2] European Medicines Agency. (n.d.). European public assessment reports (EPAR) and product information. https://www.ema.europa.eu/
[3] World Health Organization. (n.d.). WHO International Nonproprietary Names (INN) and substance information. https://www.who.int/teams/health-product-and-policy-standards/inn
